|1.||Gómora-Arrati, Porfirio: 2 articles (02/2011 - 02/2008)|
|2.||Beyer, Carlos: 2 articles (02/2011 - 02/2008)|
|3.||Etgen, Anne M: 2 articles (02/2011 - 02/2008)|
|4.||Lima-Hernández, Francisco Javier: 2 articles (02/2011 - 02/2008)|
|5.||González-Flores, Oscar: 2 articles (02/2011 - 02/2008)|
|6.||Meresman, Gabriela F: 2 articles (09/2003 - 09/2003)|
|7.||Barañao, Rosa I: 2 articles (09/2003 - 09/2003)|
|8.||Sueldo, Carlos: 2 articles (09/2003 - 09/2003)|
|9.||Tesone, Marta: 2 articles (09/2003 - 09/2003)|
|10.||Bruner-Tran, Kaylon L: 1 article (01/2016)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
03/01/2007 - "Antide 10(-5) M increased the %ApC in EEC from patients with endometriosis and controls (P < 0.01). "
01/01/2006 - "Because of less adnexal and cul-de-sac adhesions, the number of baboons with endometriosis of stage II, III, or IV was lower among baboons treated with r-hTBP1 or Antide than among controls. "
01/01/2006 - "In the first part, baboons treated with r-hTBP1 or with Antide (Bachem) had a lower endometriosis rAFS score, a lower surface area and estimated volume of peritoneal endometriotic lesions, and a lower histological confirmation rate compared with controls. "
07/01/1990 - "Fertility (rats without endometriosis) was assessed by mating vehicle-and Antide-treated rats at spontaneous proestrus (n = 8) for eight posttreatment cycles as well as after follicular stimulation (n = 2). "
07/01/1990 - "Cyclic rats with (n = 56) and without (n = 18) surgically induced endometriosis received Antide (2 mg/kg) or vehicle at noon on days 0 (proestrus), 3, 6, and 9. Rats were killed at noon on days 0, 6, 12, 18, 24, 30, 42, and 165. "
|3.||Body Weight (Weight, Body)
04/01/2006 - "CL were collected from monkeys during the early (d 3-5 after the LH surge) to very late (d 18-19) luteal phase and from controls or animals receiving GnRH antagonist (Antide, 3 mg/kg body weight). "
03/01/2005 - "Rhesus monkeys either were untreated (controls, CTRL; n = 3) or received the GnRH antagonist Antide (ANT; 3 mg/kg body weight, n = 3) to inhibit pituitary LH secretion on day 6 of the luteal phase in spontaneous menstrual cycles. "
01/01/2011 - "ICV injection of the MC4R agonist, melanotan II (80 pmol/g body weight; BW), significantly reduced food intake, and its anorexigenic effect was suppressed by ICV pre-administration of the GnRH type I receptor antagonist, antide (100 pmol/gBW). "
05/01/2003 - "In a subsequent experiment, antide, a GnRH-I receptor antagonist, was administered (100 microg/kg body weight) together with a single injection of GnRH-I or GnRH-II (1 microg/kg body weight). "
07/01/1994 - "While buserelin caused a maximum 16% inhibition of growth, antide had no effect on tumor growth at the same doses. "
06/01/1994 - "The GnRH antagonist Antide (10(-6) to 10(-8) M) blocked secretory increases in all GnRH-responsive tumors. "
12/20/1990 - "In addition, using the rat Dunning R 3327 prostatic carcinoma model, 10 mg/kg antide given subcutaneously every 6 weeks for a total period of 26 weeks, had an inhibitory effect on tumor growth identical to that of castration emphasizing the suitability of this compound for treatment of prostatic cancer."
07/01/1994 - "The objective was to evaluate the possible direct anti-tumor effects of the GnRH agonists buserelin and leuprolide acetate and the GnRH antagonist antide on ovarian cancer cell lines in culture. "
02/11/2008 - "By contrast, icv injection of Antide failed to interfere with the facilitatory effect of the synthetic progestin megestrol acetate on lordosis and proceptive behaviors. "
02/11/2008 - "Similarly, icv Antide blocked the stimulatory effect on both lordosis and proceptive behaviors elicited by progesterone and its ring A-reduced metabolites: 5alpha-pregnandione (5alpha-DHP), 5alpha-pregnan-3alpha-ol-20-one (5alpha,3alpha-Pgl) and 5beta-pregnan-3beta-hydroxy-20-one (5beta,3beta-Pgl) in ovx, E2B-primed rats. "
02/11/2008 - "Icv injection of Antide, a GnRH-1 receptor antagonist, significantly depressed lordosis behavior in ovx, E2B-primed rats treated with icv GnRH. "
05/01/2006 - "The LHRH antagonist, Antide, was capable of inhibiting LHRH-facilitated lordosis, without affecting LHRH-(1-5)-facilitated lordosis. "
02/01/2011 - "Icv injection of either antide or RU486 1h before leptin significantly depressed leptin facilitation of lordosis. "
|2.||Gonadotropin-Releasing Hormone (GnRH)
|4.||Mifepristone (RU 486)
|7.||Megestrol Acetate (Borea)
|8.||Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
|9.||Medroxyprogesterone Acetate (Depo-Provera)